Investors & Media

Transformative science, targeted medicines

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4 Statement of changes in beneficial ownership of securities View HTML
0001415889-25-018073.pdf
0001415889-25-018073.rtf
0001415889-25-018073.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001415889-25-018069.pdf
0001415889-25-018069.rtf
0001415889-25-018069.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001415889-25-018078.pdf
0001415889-25-018078.rtf
0001415889-25-018078.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001415889-25-018075.pdf
0001415889-25-018075.rtf
0001415889-25-018075.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001415889-25-018082.pdf
0001415889-25-018082.rtf
0001415889-25-018082.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001415889-25-018084.pdf
0001415889-25-018084.rtf
0001415889-25-018084.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001415889-25-018086.pdf
0001415889-25-018086.rtf
0001415889-25-018086.xls
8-K Report of unscheduled material events or corporate event View HTML
0001558370-25-008742.pdf
0001558370-25-008742.rtf
0001558370-25-008742.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
SC TO-T Tender offer schedule and amendment filed by a third party. View HTML
0001193125-25-141704.pdf
0001193125-25-141704.rtf
0001193125-25-141704.xls
SC 14D9 Solicitation/recommendation statements View HTML
0001193125-25-141740.pdf
0001193125-25-141740.rtf
0001193125-25-141740.xls